What side effects does Mavyret (glecaprevir/pibrentasvir) cause?
Mavyret (glecaprevir/pibrentasvir) is used to treat chronic hepatitis C. The most commonly reported side effects are generally mild and tend to happen during treatment.
Commonly reported effects include fatigue (cansancio), headache, nausea, and diarrhea [1]. Some people also report insomnia or general weakness, though these are less consistently listed across sources [1].
What are the serious side effects to watch for?
Serious side effects are less common, but you should get urgent medical care if you develop signs of an allergic reaction (such as swelling of the face/lips, trouble breathing, or widespread rash).
Because Mavyret can affect the liver and drug interactions matter, you should also seek prompt evaluation if you notice worsening jaundice (yellowing of the skin/eyes), dark urine, severe abdominal pain, or extreme tiredness—symptoms that can suggest significant liver problems [1].
How do Mavyret side effects compare with other hepatitis C treatments?
Mavyret is a direct-acting antiviral regimen designed for short-course treatment (often 8 weeks depending on the patient). Side effects are typically similar in type across modern hepatitis C therapies, with fatigue, headache, and gastrointestinal symptoms being among the most frequent [1]. The overall severity tends to be low for many patients, but individual tolerability varies.
Can side effects get worse if I take it with other medicines?
Yes. Drug interactions can change how safe and tolerable a regimen is. Mavyret has important interaction cautions, and taking it with certain other medicines can raise the risk of liver problems or reduce effectiveness.
If you’re asking because you have other prescriptions (or supplements), share the names with your clinician or pharmacist so they can check interactions before or during treatment [1].
When do side effects usually start and when do they go away?
Side effects—when they occur—often start during the course of treatment and may lessen after completing therapy. Many people notice improvement soon after the last dose, but exact timing depends on the person and the symptoms.
Who should be extra cautious?
Extra caution is needed if you have:
- Significant liver disease or a history of liver decompensation
- Complex medication regimens that could interact with Mavyret
Your prescriber may monitor you more closely during treatment if you’re higher risk [1].
Sources
- Mavyret (glecaprevir and pibrentasvir) Prescribing Information – AbbVie. Side effects and safety information.